🔗 Share this article

Given that the US proceeds with sweeping changes to its vaccine schedules, an unexpected name appears unexpectedly: Høeg, a US-based physician and epidemiologist who initially gained attention by casting doubt on coronavirus vaccinations during the global health crisis and has zeroed in on possible fatalities following COVID-19 immunization in her short tenure at the FDA.

Scheduled Changes to Childhood Immunization Program

Health officials planned to announce sweeping revisions to the childhood vaccine schedule in December, aligning the US with Denmark’s immunization schedule, according to reports – a significant shift that would put the US out of alignment with many the world with no evidence for public health gain. This reveal has been delayed until the coming year.

Rather than the director of the vaccine center, Tracy Beth Høeg is set to speak at the gathering. She was recently named interim head of the FDA’s CDER, the fifth individual to head the division this calendar year.

A Shift at the Agency

Høeg's temporary position could signify a strengthened alliance between the pharmaceutical and vaccine divisions as Dr. Høeg and Prasad consolidate power at the regulatory agency – and it signals a greater focus upon rolling back long-standing immunizations at the FDA.

Dr. Høeg has frequently advocated for discontinuing some childhood vaccine recommendations in the US so as to align more like the Danish model, a society with comprehensive healthcare and a population approximately the size of Wisconsin’s.

In her initial comments, she has continued to focus on vaccination policy – typically the responsibility of Dr. Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than pharmaceutical oversight.

Questions Over Expertise

The appointee has little discernible track record in medication creation, oversight or leadership, which has been typical for past leaders of the biologics center. She has been employed at the FDA as a top consultant to the FDA chief and the vaccine center since earlier this year.

“She doesn’t seem to have the requisite experience” for running the pharmaceutical oversight division, remarked Dr. Jonathan Howard. “She has not conducted a scientific study. She lacks experience in managing a sizeable institution. She is not an expert in drug approvals.”

Past commissioners of CBER would “grasp legal statutes and the underlying principles of pharmaceutical innovation”, said a former acting FDA commissioner. “Frankly, she has not acquired the type of experience that former directors who led the center have had.”

This division has an immense range of responsibilities at the agency, Woodcock stated.

“The public just zeroes in on the new drug program, but the off-patent medication office approves thousands of off-brand pharmaceuticals. There is also a biologic copycat branch, over-the-counter program and so forth, and each of these need to be managed,” Woodcock noted. “The responsibility you neglect, that is precisely what that I always told people is going to bite you.”

Additionally, a significant leadership element to the job, which oversees over 5,000 staff members. “It’s a huge administrative position, if you perform it correctly,” she said.

Response and Controversial Initiatives

In response to inquiries about Dr. Høeg's credentials and whether this assignment indicates more teamwork among agency officials on immunizations, a press secretary said that the “concerns stem from inaccurate presumptions”.

“This background matches the responsibilities of her job,” the spokesperson explained, citing the time Dr. Høeg spent counseling the FDA commissioner on “drug safety and approval science, including computerized risk analysis and immunization monitoring”.

In her interim role, Dr. Høeg takes over the agency head's new expedited review system, a controversial one-day drug-approval program that reportedly worried her former heads. “How are these medications being selected for this fast-track system? Who makes the decisions?” Dr. Howard asked. “There’s a lot of confidentiality happening at the agency right now.”

Overall, he stated, “the Food and Drug Administration appears to be shifting towards less stringent regulations of most medications, aside from vaccines.”

Documented Past Work on Immunizations

Concerning vaccines, Dr. Høeg has a more established, if troubling, past, Howard have noted. She released a analysis using unverified crowd-sourced reports to estimate the rate of myocarditis following COVID-19 immunization. She consulted for the state of Florida chief medical officer Dr. Joseph Ladapo, who reportedly have altered data to imply Covid vaccines are riskier than they are.

Included in her “policy goals” for the current administration encompassed revising rules for novel immunizations and ending “non-essential” vaccines, she remarked following the vote on a online show. At the agency, Høeg has reportedly suggested barring young men from obtaining Covid vaccines.

“She’s an all-around dogmatist who commences with her preconceived notions and tailors the evidence to retrofit the science in a extremely misleading, dishonest way,” Howard said.

Taking Control and a “Campaign of Retribution”

Dr. Høeg aligned with other dissenters, {like|